Citations

Prospective Evaluation of the Predictive Value of Faecal Calprotectin in Quiescent Crohn’s Disease

BÜHLMANN fCAL® ELISA Citation Naismith, Smith LA, Barry SJ, Munro JI, Laird S, Rankin K, Morris AJ, Winter JW, Gaya DR. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn’s disease. J Crohns Colitis. 2014 Sep;8(9):1022-9. doi: 10.1016/j.crohns.2014.01.029. “The FC result, obtained by non-invasive means, can provide prognostic information for both the patient
Read more

Estimation of the Possible Economic Effects of Pre-Endoscopic Screening with F-calprotectin, Clinical Biochemistry

BÜHLMANN fCAL® ELISA Citation: Mindemark, M. & Larsson, A.  Ruling out IBD: Estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin, Clinical Biochemistry.  Clin Biochem. 2012 May;45(7-8):552-5. doi: 10.1016/j.clinbiochem.2011.10.015. “The estimated demand for colonoscopies was reduced by 50% to 67%. This corresponded to a cost avoidance of approximately up to €2.13 million.”

Read more

Fecal Calprotectin is Equally Sensitive in Crohn’s Disease Affecting the Small Bowel and Colon

BÜHLMANN fCAL® ELISA Citation: Jensen, M.D.,  Kjeldsen J, Nathan T. Fecal calprotectin is equally sensitive in Crohn’s disease affecting the small bowel and colon. Scand J Gastroenterol. 2011 Jun;46(6):694-700. doi: 10.3109/00365521.2011.560680. “The first study to show that fecal calprotectin is equally sensitive in colonic and small bowel CD.” Read More
Read more

Comparative Study of the Quantum Blue Rapid Test and an Established ELISA Method

Quantum Blue®  fCAL Citation Coorevits, L, Baert F , Vanpoucke H.  Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method, Clinical chemistry and laboratory medicine: CCLM / FESCC. . 2013 Apr; 51(4):825-31. DOI:10.1515/cclm-2012-0386. “…we may conclude that the POCT can serve as reliable alternative to the time consuming ELISA…” Read More
Read more